Effective Health Care

Safety and Efficacy of Deflazacort Nomination Summary Document

Results of Topic Selection Process & Next Steps

- *Safety and efficacy of deflazacort vs. prednisolone in prevention of systemic autoimmune rheumatic diseases* does not represent a healthcare intervention or activity that is available in the US and therefore does not fall within the domain of the Effective Health Care Program. No further activity will be undertaken on this topic.
    - In August 2015, Marathon Pharmaceuticals began the FDA's New Drug Application (NDA) process for the use of deflazacort to treat Duchenne Muscular Dystrophy. If approved, deflazacort will be available in the US in early 2017.

Topic Description

Nominator(s): Individual

Nomination Summary: The nominator is interested in safety and efficacy of deflazacort compared to prednisolone for systemic autoimmune rheumatic diseases, in particular female patients between 20 and 40 with a diagnosis of lupus with lupus nephritis.

Considerations

- The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews focus attention on the evidence from research studies about the effectiveness and safety of a clinical intervention.
- The topic does not meet EHC Program appropriateness criteria. (For more information, see http://effectivehealthcare.ahrq.gov/index.cfm/submit-a-suggestion-for-research/how-are-research-topics-chosen/.)